Medindia

X

Kendle Appoints Robert Shepard, MD, FACP Executive Director, Oncology

Thursday, June 2, 2011 General News J E 4
Advertisement
Oncology thought leader with more than four decades of oncology research experience adds valuable leadership and expertise for key therapeutic area

CINCINNATI, June 2, 2011 /PRNewswire/ -- Kendle (Nasdaq: KNDL), a leading, global full-service clinical research organization (CRO), today announced the appointment of Robert Shepard, MD, FACP, as Executive Director, Oncology, Medical Affairs effective immediately.  Dr. Shepard is a leading authority on clinical development in oncology, bringing more than four decades of oncology research experience to Kendle. He will oversee the development of oncology programs for customers worldwide, providing medical, safety and scientific support to clinical research teams, investigators and customer contacts.  

"We are delighted Dr. Shepard has joined Kendle," said Melanie A. Bruno, PhD, Vice President, Regulatory and Medical Affairs. "His unsurpassed experience and expertise will be invaluable to our customers as we work with them to bring new oncology therapies to market."  

Dr. Shepard has extensive research credentials in hematology and oncology; is board certified in oncology, hematology and internal medicine; and has a wide array of experience in translational medicine and clinical research. He has been actively involved in oncology research since 1970 and has been responsible for the complete clinical development of several drugs and immune therapies for biopharmaceutical companies, including serving as the consulting Chief Medical Officer for six companies.

Dr. Shepard is a Magna cum Laude graduate of Harvard University in biochemical sciences and molecular biophysics and studied in the Harvard-M.I.T. Health Sciences program.  He earned his medical degree from Duke University in the Medical Scientist Training Program, which included two years of graduate training in immunology.  Dr. Shepard completed a fellowship in hematology and oncology at the Tufts-New England Medical Center where he conducted laboratory research in leukemias, myeloma and myelodysplasia. Dr. Shepard also completed a postdoctoral fellowship in pharmacology and molecular genetics at the Dana-Farber Cancer Center and Harvard Medical School.  He has held academic appointments at Harvard University, Tufts University and the University of Virginia.

To meet Dr. Shepard at the American Society of Clinical Oncology (ASCO) Annual Meeting June 3-7 in Chicago and learn more about Kendle's expertise in oncology clinical development programs, please email info@kendle.com or contact us at +1 800 733 1572.

About Kendle

Kendle International Inc. (Nasdaq: KNDL) is a leading global clinical research organization providing the full range of early- to late-stage clinical development services for the world's biopharmaceutical industry. Our focus is on innovative solutions that reduce cycle times for our customers and accelerate the delivery of life-enhancing products to market for the benefit of patients worldwide. As one of the world's largest global providers of Phase I-IV services, we offer experience spanning more than 100 countries, along with industry-leading patient access and retention capabilities and broad therapeutic expertise, to meet our customers' clinical development challenges.

For more information, please visit www.kendle.com.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements relating to Dr. Shepard's anticipated contribution to programs for Kendle customers. Words such as "anticipate," "believe," "plan," "estimate," "expect," "intend," "will," "should," "may," and other similar expressions are intended to identify forward-looking statements. Such statements are based upon the current beliefs and expectations of Kendle's management and involve a number of significant risks and uncertainties, many of which are difficult to predict and are generally beyond the control of Kendle. Actual results may differ materially from the results anticipated in these forward-looking statements. Additional factors that could cause Kendle's results to differ materially from those described in the forward-looking statements can be found in the periodic reports filed with the Securities and Exchange Commission, which are available at the Securities and Exchange Commission's website (http://www.sec.gov) at no charge. Kendle assumes no responsibility to update any forward-looking statements as a result of new information or future developments except as expressly required by law.

SOURCE Kendle International Inc.

Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
Investment in Oncology Drug Development Remains St...
S
Morphotek®, Inc. Announces Initiation of MORAb-004...